-
ALX Oncology Holdings Inc NASDAQ:ALXO ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.
Location: | Website: alxoncology.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-28.64M
Cash
156.7M
Avg Qtr Burn
-33.83M
Short % of Float
46.25%
Insider Ownership
1.92%
Institutional Own.
-
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Evorpacept (ALX148) + Keytruda Details Cancer, Platinum-resistant ovarian cancer | Phase 2 Data readout | |
Evorpacept (ALX148) + Herceptin® (trastuzumab)+Cyramza® (ramucirumab) and paclitaxel Details Cancer, Gastric cancer | Phase 2 Data readout | |
Evorpacept (ALX148) + Keytruda Details Head and neck cancer, Cancer | Phase 2 Data readout | |
Evorpacept + cetuximab + pembrolizumab Details Cancer, Metastatic colorectal cancer | Phase 2 Update | |
Evorpacept (ALX148) + Sarclisa Details Cancer, Multiple myeloma | Phase 1/2 Data readout | |
Evorpacept (ALX148) + rituximab and lenalidomide Details Non-Hodgkin lymphoma, Cancer | Phase 1/2 Data readout | |
Evorpacept (ALX148) + ENHERTU® Details Breast cancer, Cancer | Phase 1 Data readout | |
Evorpacept + enfortumab vedotin-ejfv/PADCEV® Details Cancer, Urothelial cancer | Phase 1 Data readout | |
Evorpacept (ALX148) + Zanidatamab Details Breast cancer, Cancer | Failed Discontinued | |
Evorpacept (ALX148) + Venetoclax Details Cancer, Acute myeloid leukemia | Failed Discontinued | |
Evorpacept (ALX148) combo w/ azacitidine Details Myelodysplastic syndrome, Cancer | Failed Discontinued |